

August 01, 2025

To,  
National Stock Exchange of India Ltd,  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block, Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051

Company Symbol: **DENTALKART**,  
ISIN: INE0N5801013

Subject: **Outcome of Board Meeting pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) regulations, 2015**

Dear Sir / Madam,

With reference to the subject cited, this is to inform the Exchange that the meeting of the Board of Directors of Vasa Denticity Limited held on Friday, August 01, 2025 at 10:00 A.M. through video conferencing deemed to be held at the registered office of the Company, the following were considered and approved:

#### **1. Strategic Acquisition of 51% Equity Stake in IDS Denmed Private Limited**

The Board approved a strategic investment in IDS Denmed Private Limited, India's leading offline dental distribution company, as follows:

Acquisition of 19.92% equity stake through cash consideration of up to ₹ 50,00,92,400/- by acquiring 9,962 equity shares at a price of ₹ 50,200 per share (including premium).

Further acquisition of up to 31.08% equity stake in IDS Denmed by way of preferential allotment of up to 12,34,185 equity shares of the Company at a price of ₹ 632/- per share (face value ₹ 10 + premium ₹ 622/- on a share swap basis.)

Upon completion of both tranches, the Company will hold a controlling stake of 51% in IDS Denmed Private Limited, making it a subsidiary of Vasa Denticity Limited.

The transaction is in line with the Company's strategic roadmap to build India's most integrated dental supply ecosystem. The proposed preferential issue is subject to approval of shareholders and requisite regulatory approvals.

***Disclosures in accordance with Regulation 30 read with Schedule III and SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are enclosed as Annexure I.***

Considered and approved approval for infusion of up to up to ₹ 50,00,92,400.00/- (Rupees Fifty Crores Ninety Two Thousand Four Hundred) and execute a Shareholders' Agreement ('SHA') with IDS Denmed Private Limited "IDS Denmed", to acquire and hold 19.92% equity stake in IDS Denmed.

Pursuant to the approval of the Board, the Company has today executed the SHA with IDS Denmed pursuant to which the Company will acquire 9962 equity shares (19.92% equity stake) aggregating to 50,00,92,400.00/- Rupees Fifty Crores Ninety Two Thousand Four Hundred).

Issuance and allotment of up to 12,34,185 (Twelve Lakh Thirty Four Thousand One Hundred Eighty Five) fully paid up equity shares of the Company having face value of ₹ 10/- each, at an issue price of ₹ 632/- per equity share (including premium of INR 622/-) aggregating to ₹ 78,00,04,920.00/-(Seventy Eight Crores Four Thousand Nine Hundred and Twenty rupees), to shareholders of IDS Denmed to discharge part consideration, for the acquisition of up to 31.08% equity stake, on fully diluted basis, in IDS Denmed Private Limited, on a preferential basis ("Preferential Issue"), in accordance with the provisions of Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, the Companies Act, 2013, other applicable laws and subject to approval of the shareholders of the Company, and such other regulatory/ statutory approvals as may be required.

2. Approved convening of Extraordinary General Meeting ('EGM') of the members of the Company on Monday, August 25, 2025 through Video Conferencing ('VC')/ Other Audio-Visual Means ('OAVM') as per the relevant circulars of MCA and SEBI for obtaining the shareholders' approval for the above mentioned items. The EGM notice shall be submitted to stock exchanges when it will be circulated to members of the Company as per the applicable provision of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015;
3. Appointment of Mr. Loveneet Handa (FCS Membership No. 9055 & COP 10753), Proprietor of Loveneet Handa & Associates having peer review certificate number: 5316/2023 as Scrutinizer for scrutinizing voting of EGM;

The meeting concluded at 12:05 P.M.

Kindly arrange to take the same on your records.

For Vasa Denticity Limited

**NIDHI**  
**COMPANY SECRETARY & COMPLIANCE OFFICER**  
**MEMBERSHIP No: A74591**

### Annexure - I

**Disclosure as per SEBI (LODR) Regulations, 2015 is given below:**

**“Strategic Acquisition” of the 51% stake in IDS Denmed Private Limited:**

Sl. No.	Particulars	IDS Denmed Private Limited
1	Name of the proposed entity, details in brief such as size, turnover etc.	<p>IDS Denmed Private Limited.</p> <p>The Company has an authorized share capital of Rs. 50,00,000 divided into 5,00,000 equity shares of Rs.10/- each and paid up capital of Rs. 5,00,000 divided into 50,000 shares of Rs. 10/- each.</p> <p>The Company has achieved a turnover &amp; EBIDTA for FY25 is</p> <p>Turnover: of Rs. 240.1 crores (Un-Audited) EBIDTA: Rs. 20.7 crores (Un-Audited)</p>
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms length”;	No, the acquisition would not fall within related party transaction(s) and the promoter/ promoter group/ group companies do not have any interest in the entity being acquired.
3	Industry to which the entity being acquired belongs	IDS Denmed Private Limited is engaged in dental industry providing vast range of dental product. since its inception driven by customer centric approach for service and support. IDS exclusively collaborated with big brands like Bego from Germany, VITA from Germany, J.Morita from Japan, Melag from Germany, Marathon from Korea and many more such brands. Today IDS exclusively imports 50+ brands from around the globe & engages in the distribution of same which reaches almost all parts of India.
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	<p>Strategic Expansion Through Acquisition: Vasa Denticity Limited to Acquire IDS Denmed Private Limited.</p> <p>Vasa Denticity Limited, a leading Indian dental-tech company specializing in dental products through its online platform Dentalkart.com, is taking a significant step towards expansion. The company offers an extensive range of dental supplies from numerous reputed brands and also boasts a growing portfolio of</p>

		<p>proprietary products, manufactured under strict quality specifications.</p> <p>In alignment with its strategic objective to strengthen its market position and broaden its national footprint in the dental supplies industry, Vasa Denticity Limited is set to acquire IDS Denmed Private Limited.</p> <p>This acquisition will serve as a catalyst for organic growth, enabling synergies in manufacturing, distribution, and innovation. The combined entity will be better positioned to offer a more comprehensive product portfolio, enhance operational efficiencies, and reach a wider customer base across global markets.</p> <p>The integration of IDS Denmed's capabilities and infrastructure with Vasa Denticity's established digital platform and brand recognition, margin expansion will create significant value for all stakeholders—including customers, partners, employees, and shareholders at large.</p> <p>This strategic move underscores Vasa Denticity's commitment to long-term growth and leadership in the global dental products market.</p>
5	Brief details of any governmental or regulatory approvals required for the acquisition;	Appropriate approvals will be taken from the shareholders in the general meeting and from the NSE Limited like In-principle approval for issue, allotment and listing/ trading.
6	Indicative time period for completion of the acquisition	Within six months from the date of the decision taken by the Board of the Company.
7	Nature of consideration - whether cash consideration or share swap and details of the same	<p>Cash &amp; Swapping of Shares</p> <p><b>By cash:</b></p> <p>The cost of acquisition is of Rs. 50,200 per share, including premium of Rs. 50,190, aggregating to Rs. Rs. 50,00,92,400.00/- (Rupees Fifty Crores Ninety Two Thousand Four Hundred) by acquiring 9962 equity shares of IDS Denmed Private Limited</p> <p><b>By Swap:</b></p> <p>12,34,185 Equity shares are proposed to be issued at an issue price of Rs. 632/- each including premium of Rs. 622/- per share which amounts to Rs. 78,00,04,920.</p>

		Acquisition is done on swap basis, Valuation report from the registered valuer is obtained and uploaded on the website of the Company.
8	Cost of acquisition or the price at which the shares are acquired	<p>The cost of acquisition is of Rs. 1,28,01,00,000 having 25500 equity shares at Rs. 50,200 per share, including premium of Rs. 50,190. Which constitutes 51% stake in IDS Denmed.</p> <p>Out of which 9962 equity shares shall be acquire by cash aggregating to Rs. Rs. 50,00,92,400.00/- (Rupees Fifty Crores Ninety Two Thousand Four Hundred).</p> <p>Further, 12,34,185 Equity shares are proposed to be issued at an issue price of Rs. 632/- each including premium of Rs. 622/- per share which amounts to Rs. 78,00,04,920 by acquiring 15538 equity shares of IDS Denmed Private Limited</p>
9	Percentage of shareholding/ control acquired and / or number of shares acquired	Up to 25500 Equity Shares (51%)
10	Brief background about the entity acquired in terms of products/ line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>a. Brief background: as explained in point no 3 &amp; 4 above</p> <p>b. Date of incorporation: April 11<sup>th</sup> 2006</p> <p>c. Turnover &amp; EBIDTA of last 3 Financial Years</p> <p><b>Financial Year: 2024-25</b>  Turnover: Rs. 240.10 Crores (Un-Audited)  EBIDTA: Rs. 20.70 crores (Un-Audited)</p> <p><b>Financial Year: 2023-24</b>  Turnover: Rs. 246.21 crores  EBIDTA: Rs. 23.31 crores</p> <p><b>Financial Year: 2022-23</b>  Turnover: Rs. 215.84 Crores  EBIDTA: Rs. 23.20 Crores</p> <p>d. Country of Incorporation: India</p>

### DETAILS OF THE PROPOSED ALLOTTEES

Sr. No.	Name of the Proposed Allottees	No. of Equity Shares to be swapped in IDS	No. of Equity Shares to Issue and Allot of Vasa Denticity Limited against swapping	Current Status / Category	Proposed Status / Category
1.	Anju Malhotra	1243	98731	Non-Promoter	Non-Promoter
2.	Dimple Malhotra	1243	98731	Non-Promoter	Non-Promoter
3.	Parveen Malhotra	5983	475231	Non-Promoter	Non-Promoter
4.	Sanjay Malhotra	5982	475152	Non-Promoter	Non-Promoter
5.	Santosh Malhotra	1087	86340	Non-Promoter	Non-Promoter
	<b>Total</b>	<b>15,538</b>	<b>12,34,185</b>		